Back to Awarded Treatment Trials


Awarded Trial: 14T-008

Grant ID

14T-008

Illness

Bipolar disorder

Primary Drug/Intervention

Metformin

Primary Dosage

850 mg twice daily

Secondary Drug Intervention

N/A

Secondary Dosage

N/A

Other Drug/Intervention

N/A

Other Dosage

N/A

Status

Enrolling

Investigator

Calkin

Sample Size

60

Duration of Study Period for Each Subject

196 days

Outcome Measurements

Primary outcome measures: Effect of metformin on mood symptoms using the MADRS and BDI scales. Improvement in the MADRS and BDI scores will be compared with HOMA-IR to determine if degree of improvement in symptoms correlates with degree of improvement in IR.

Results

N/A

Publication

N/A

Link

N/A

PI Name

Cindy Calkin

Degree

MD

Center

N/A

Institution

Capital District Health Authority

Address

N/A

City or Town

N/A

State or Province

N/A

Zip or Postal Code

N/A

Country

Canada

Email Address

cindy.calkin@cdha.nshealth.ca